BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Zhang J, Wang X, Tian JJ, Zhu R, Duo RX, Huang YC, Shen HL. Iguratimod in treatment of primary Sjögren’s syndrome concomitant with autoimmune hemolytic anemia: A case report. World J Clin Cases 2022; 10(4): 1286-1290 [PMID: 35211561 DOI: 10.12998/wjcc.v10.i4.1286]
URL: https://www.wjgnet.com/2307-8960/full/v10/i4/1286.htm
Number Citing Articles
1
Pedro N. S. L. Silva, João A. Baptista, Nuno A. S. Santos, Ricardo A. E. Castro, Manuela Ramos Silva, João Canotilho, M. Ermelinda S. Eusébio, Teresa M. R. Maria. Insights into the Solid-State Landscape of Iguratimod, a Disease-Modifying Antirheumatic DrugCrystal Growth & Design 2026; 26(6): 2531 doi: 10.1021/acs.cgd.5c01817
2
KD Suryana, B Alodia. Autoimmune Hemolytic Anemia in Non-Hodgkin’s Lymphoma: Pathogenesis, Diagnosis, and ManagementNigerian Journal of Clinical Practice 2025; 28(12): 1359 doi: 10.4103/njcp.njcp_826_24
3
Qi Zhang, Xi-Rui Yang, Yao Deng. Iguratimod Alleviates Experimental Sjögren’s Syndrome by Inhibiting NLRP3 Inflammasome ActivationCell Biochemistry and Biophysics 2024; 82(3): 2275 doi: 10.1007/s12013-024-01337-2